New Tool Predicts Survival for Patients With Lung Cancer and
A new, user-friendly index called the Graded Prognostic Assessmentfor Lung Cancer Using Molecular Markers (Lung-molGPA) may help guide clinical decision making and stratification of future clinical trials for patients with lung cancer (JAMA Oncol 2016 Nov 17. [Epub ahead of print], PMID: 27892978).

Investigators at the University of Minnesota updated the existing Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) with new gene and molecular alteration data for use in patients with non-small cell lung cancer (NSCLC) and brain metastases. They retrospectively analyzed data from multiple institutions on 2,186 patients diagnosed with NSCLC and new brain metastases between 2006 and 2014. In addition to the four variables used for the DS-GPA—patient age, Karnofsky Performance Status, extracranial metastases and number of brain metastases—the researchers also considered gene mutation status (EGFR-, ALK- or KRAS­-positive), pack-years of tobacco use, sex, race, histopathologic grade and total volume of brain metastases....